Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label study of the effect of CellCept , Zenepax (daclizumab), and corticosteroids, with delayed introduction of sirolimus plus discontinuation of ciclosporin, on renal function in kidney transplant patients

Next Previous
X
Search
Trial Profile

A randomized, open-label study of the effect of CellCept , Zenepax (daclizumab), and corticosteroids, with delayed introduction of sirolimus plus discontinuation of ciclosporin, on renal function in kidney transplant patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Oct 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Ciclosporin; Sirolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms CONCEPT
  • Sponsors Roche

    • Most Recent Events

    • 19 Sep 2011 Pharmacodynamic substudy results published in the American Journal of Transplantation.
    • 07 Sep 2011 Five-year renal function data presented at the 15th Congress of the European Society for Organ Transplantation.
    • 26 May 2011 Vascular endothelial growth factor substudy results published in Nephrology Dialysis Transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top